Hanall Biopharma Statistics

Total Valuation

KRX:009420 has a market cap or net worth of KRW 1.44 trillion. The enterprise value is 1.41 trillion.

Market Cap	1.44T
Enterprise Value	1.41T

Important Dates

The last earnings date was Friday, March 7, 2025.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:009420 has 50.77 million shares outstanding. The number of shares has increased by 0.04% in one year.

Current Share Class	n/a
Shares Outstanding	50.77M
Shares Change (YoY)	+0.04%
Shares Change (QoQ)	+0.08%
Owned by Insiders (%)	0.37%
Owned by Institutions (%)	18.08%
Float	34.46M

Valuation Ratios

PE Ratio	n/a
Forward PE	142.07
PS Ratio	10.33
PB Ratio	8.53
P/TBV Ratio	8.77
P/FCF Ratio	186.13
P/OCF Ratio	n/a
PEG Ratio	3.07

Financial Ratio History

Enterprise Valuation

EV / Earnings	-783.12
EV / Sales	10.17
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	183.12

Financial Position

The company has a current ratio of 2.46, with a Debt / Equity ratio of 0.01.

Current Ratio	2.46
Quick Ratio	1.29
Debt / Equity	0.01
Debt / EBITDA	0.43
Debt / FCF	0.19
Interest Coverage	3.25

Financial Efficiency

Return on equity (ROE) is -1.02% and return on invested capital (ROIC) is 0.08%.

Return on Equity (ROE)	-1.02%
Return on Assets (ROA)	0.06%
Return on Invested Capital (ROIC)	0.08%
Return on Capital Employed (ROCE)	0.13%
Revenue Per Employee	449.66M
Profits Per Employee	-5.84M
Employee Count	309
Asset Turnover	0.61
Inventory Turnover	1.88

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.74% in the last 52 weeks. The beta is 0.68, so KRX:009420's price volatility has been lower than the market average.

Beta (5Y)	0.68
52-Week Price Change	-25.74%
50-Day Moving Average	37,024.00
200-Day Moving Average	37,190.00
Relative Strength Index (RSI)	29.43
Average Volume (20 Days)	553,399

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:009420 had revenue of KRW 138.94 billion and -1.80 billion in losses. Loss per share was -35.59.

Revenue	138.94B
Gross Profit	73.21B
Operating Income	230.47M
Pretax Income	-183.20M
Net Income	-1.80B
EBITDA	3.35B
EBIT	230.47M
Loss Per Share	-35.59

Full Income Statement

Balance Sheet

The company has 24.71 billion in cash and 1.45 billion in debt, giving a net cash position of 23.26 billion or 458.16 per share.

Cash & Cash Equivalents	24.71B
Total Debt	1.45B
Net Cash	23.26B
Net Cash Per Share	458.16
Equity (Book Value)	168.35B
Book Value Per Share	3,316.25
Working Capital	50.63B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 9.36 billion and capital expenditures -1.64 billion, giving a free cash flow of 7.72 billion.

Operating Cash Flow	9.36B
Capital Expenditures	-1.64B
Free Cash Flow	7.72B
FCF Per Share	152.04

Full Cash Flow Statement

Margins

Gross margin is 52.69%, with operating and profit margins of 0.17% and -1.30%.

Gross Margin	52.69%
Operating Margin	0.17%
Pretax Margin	-0.13%
Profit Margin	-1.30%
EBITDA Margin	2.41%
EBIT Margin	0.17%
FCF Margin	5.56%

Dividends & Yields

KRX:009420 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.04%
Shareholder Yield	-0.04%
Earnings Yield	-0.13%
FCF Yield	0.54%

Stock Splits

The last stock split was on April 28, 2006. It was a forward split with a ratio of 10.

Last Split Date	Apr 28, 2006
Split Type	Forward
Split Ratio	10

Scores

KRX:009420 has an Altman Z-Score of 26.05.

Altman Z-Score	26.05
Piotroski F-Score	n/a